Some updates from the Michigan Department of Community Health:
Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices
The Advisory Committee on Immunization Practices (ACIP) recommends the 9-valent human papillomavirus (HPV) vaccine (9vHPV; Gardasil 9) as one of three HPV vaccines that can be used for routine vaccination. 9vHPV, quadrivalent HPV vaccine (4vHPV), or bivalent HPV vaccine can be used for routine vaccination of females. 9vHPV or 4vHPV can be used for routine vaccination of males. This report summarizes evidence considered by the Advisory Committee on Immunization Practices (ACIP) in recommending the 9-valent human papillomavirus (HPV) vaccine (9vHPV) as one of three HPV vaccines that can be used for routine vaccination and provides recommendations for use.
The recommendations are posted on the CDC website: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices
CDC Webinar Announcement: “HPV Vaccine Recommendation Update” – Friday, April 3, 11AM-12 PM ET
The CDC has rescheduled its previously postponed “HPV Vaccine Recommendation Update Webinar” for Friday, April 3, 2015 from 11:00am to 12:00pm (ET).
CDC’s Dr. Lauri Markowitz will provide an update on HPV vaccine recommendations and a review of the HPV vaccine session at last month’s meeting of the Advisory Committee on Immunization Practices (ACIP), when the ACIP voted on use of 9-valent HPV vaccine. Shannon Stokley will be available to answer questions regarding programmatic implications and Jill Roark will also be on to respond to communications-related questions.
To register for this webinar, please visit: https://attendee.gotowebinar.com/register/5730620884498357249
The FDA recently approved the use of Quadracel vaccine, manufactured by Sanofi Pasteur, for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis in children 4 through 6 years of age.
The FDA approval of Quadracel vaccine gives health care providers a new choice in combination vaccines, potentially reducing the number of vaccine injections that children 4 through 6 years of age would need. Quadracel vaccine allows health care providers the opportunity to complete the full DTaP series with combination vaccines that contain the same 5 acellular pertussis antigens.
This FDA approval is based on data from a pivotal multicenter, randomized, controlled, Phase III study designed to compare the safety and immunogenicity of Quadracel vaccine (DTaP-IPV) with DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) (DTaP) + IPOL®(Poliovirus Vaccine Inactivated) (IPV) vaccines in children 4 through 6 years of age who were previously vaccinated with DAPTACEL and/or Pentacel®(Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate [Tetanus Toxoid Conjugate] Vaccine ) (DTaP-IPV/Hib) vaccines. Results show Quadracel vaccine has similar safety and immunogenicity profiles as compared to those of separately administered DAPTACEL and IPOL vaccines.